Resumen

Este resumen es generado por inteligencia artificial y revisado por la redacción.

Colombo (Sri Lanka), 01/08/2021.- A health worker holds a vial of the Oxford Astrazeneca (Covishield) COVID-19 vaccine at a temporary vaccine center in Colombo, Sri Lanka, 01 August 2021. According to the health ministry, The Japanese government donated 728,460 doses of Oxford-AstraZeneca covishield COVID-19 vaccine under the COVAX facility on 30 July 2021. Sri Lanka is currently using Oxford AstraZeneca, China's Sinopharm, Russian Sputnik V, and Moderna Covid -19 vaccines for the Vaccine rollout. (Japón, Rusia) EFE/EPA/CHAMILA KARUNARATHNE
Colombo (Sri Lanka), 01/08/2021.- A health worker holds a vial of the Oxford Astrazeneca (Covishield) COVID-19 vaccine at a temporary vaccine center in Colombo, Sri Lanka, 01 August 2021. According to the health ministry, The Japanese government donated 728,460 doses of Oxford-AstraZeneca covishield COVID-19 vaccine under the COVAX facility on 30 July 2021. Sri Lanka is currently using Oxford AstraZeneca, China's Sinopharm, Russian Sputnik V, and Moderna Covid -19 vaccines for the Vaccine rollout. (Japón, Rusia) EFE/EPA/CHAMILA KARUNARATHNE
/ CHAMILA KARUNARATHNE
Por Agencia AFP

La Agencia Europea del Medicamento (EMA) señaló al síndrome neurológico Guillain-Barré como un posible efecto secundario “muy inusual” de la vacuna de AstraZeneca contra el COVID-19.

Conforme a los criterios de

Trust Project
Tipo de trabajo:

NoticiasInformación basada en hechos y verificada de primera mano por el reportero, o reportada y verificada por fuentes expertas.